- $7.79m
- -$2.50m
Annual income statement for IN8bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.56 | 14.7 | 28.5 | 30.3 | 30.7 |
| Operating Profit | -8.56 | -14.7 | -28.5 | -30.3 | -30.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.56 | -14.7 | -28.5 | -30 | -30.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.56 | -14.7 | -28.5 | -30 | -30.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.56 | -14.7 | -28.5 | -30 | -30.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.3 | -14.7 | -28.5 | -30 | -30.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -16.5 | -23.4 | -40.8 | -30.1 | -16.5 |
| Dividends per Share |